Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Thursday, March 31, 2022.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q1 FY2022 (2022-03-31): -393.60%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
-191.47%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Phathom Pharmaceuticals, Inc.
Market Cap
$539.20M
Return on Equity (ROE)
N/A
TTM Avg
-191.47%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$538.98M
Return on Equity (ROE)
-13.64%
TTM Avg
-19.13%
3Y Avg
-73.22%
5Y Avg
-63.52%
Market Cap
$535.00M
Return on Equity (ROE)
-24.90%
TTM Avg
-76.97%
3Y Avg
-68.04%
5Y Avg
-50.09%
Market Cap
$527.92M
Return on Equity (ROE)
N/A
TTM Avg
6.49%
3Y Avg
6.51%
5Y Avg
-75.00%
Market Cap
$528.51M
Return on Equity (ROE)
0.44%
TTM Avg
-17.98%
3Y Avg
71.24%
5Y Avg
-6.51%
Market Cap
$527.68M
Return on Equity (ROE)
-306.61%
TTM Avg
-169.61%
3Y Avg
-163.97%
5Y Avg
-73.13%
Market Cap
$556.75M
Return on Equity (ROE)
-26.37%
TTM Avg
-3503.18%
3Y Avg
-1722.33%
5Y Avg
3198.08%
Market Cap
$528.58M
Return on Equity (ROE)
-17.44%
TTM Avg
-97.25%
3Y Avg
-87.77%
5Y Avg
-77.06%
Market Cap
$560.00M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. (PHAT) | $539.20M | N/A | -191.47% | N/A | N/A |
| Monopar Therapeutics Inc. (MNPR)vs › | $538.98M | -13.64% | -19.13% | -73.22% | -63.52% |
| Shattuck Labs, Inc. (STTK)vs › | $535.00M | -24.90% | -76.97% | -68.04% | -50.09% |
| ProKidney Corp. (PROK)vs › | $527.92M | N/A | 6.49% | 6.51% | -75.00% |
| Delcath Systems, Inc. (DCTH)vs › | $528.51M | 0.44% | -17.98% | 71.24% | -6.51% |
| Nuvectis Pharma, Inc. (NVCT)vs › | $527.68M | -306.61% | -169.61% | -163.97% | -73.13% |
| CytomX Therapeutics, Inc. (CTMX)vs › | $556.75M | -26.37% | -3503.18% | -1722.33% | 3198.08% |
| Immix Biopharma, Inc. (IMMX)vs › | $528.58M | -17.44% | -97.25% | -87.77% | -77.06% |
| MiniMed Group, Inc. (MMEDV)vs › | $560.00M | N/A | N/A | N/A | N/A |
| Altimmune, Inc. (ALT)vs › | $516.91M | -19.35% | -58.07% | -51.86% | -46.32% |
ROE
N/A
ROA
-30.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2022-03-31 | -393.60% |
| 2021-12-31 | -199.41% |
| 2021-09-30 | -156.34% |
| 2021-06-30 | -120.51% |
| 2021-03-31 | -87.48% |
| 2020-12-31 | -66.44% |
| 2020-09-30 | -110.85% |
| 2020-06-30 | -110.05% |
| 2020-03-31 | -131.30% |
| 2019-12-31 | -111.92% |
